RxDoctor Payments Data

Charles Spradlin, APRN

Nurse Practitioner · Tulsa, OKNPI 1457732893

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.0% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Boston Scientific at 49.8% of the total. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,517in general payments, 2019–2025

Across 165 payments — averaging $39.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$644
  • E.r. Squibb & Sons, L.L.C.$440
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$369
  • Pfizer$337
  • Philips North America LLC$257
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$65010%
  • Food & beverage$5,86790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,517 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,796
Medicare patients
421
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$154,506
XareltoRivaroxaban19$16,867
MultaqDronedarone Hcl11$14,895
Metoprolol Succinate113$1,460
Flecainide Acetate43$1,430
Amiodarone Hcl94$1,002
Metoprolol Tartrate59$293
SotalolSotalol Hcl11$189
Carvedilol15$140
Losartan Potassium17$133
Furosemide14$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$337$154,506160 claims
Johnson & JohnsonXarelto$42$16,86719 claims
Sanofi-aventis U.S. LLCMultaq$22$14,89511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →